Denali Therapeutics Inc. (DNLI) Misses Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts DNLI Hot Sheet
Join SI Premium – FREE
Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q2 EPS of ($0.72), $0.01 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $0 versus the consensus estimate of $7.47 million.
For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
- JPMorgan Upgrades America Movil (AMX) to Overweight
- Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
